MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the FDA approval of a new physician-use continuous glucose monitoring (CGM) system, the CGMS® iPro™ Recorder. Physicians send patients home with the CGMS iPro Recorder to uncover patterns and potential problems that often go undetected with today’s standard glucose measurements like finger stick meters and HbA1c tests. The new CGMS iPro Recorder is smaller, lighter in weight and less time consuming to use than previous CGMS recorders. Physicians can now gain added clinical insights from the CGMS iPro Recorder in a matter of minutes, while improved ergonomics give patients added freedom when wearing the device. Physician services associated with CGMS iPro are reimbursed from Medicare in all 50 states and have broad private insurance reimbursement. Patients wear the CGMS iPro Recorder for three days, after which physicians can review the data and use the results to uncover glucose patterns and optimize patient therapy. Based on the detailed glycemic profiles collected from the CGMS iPro Recorder, physicians can better tailor diabetes treatment programs for each patient. This may be particularly helpful for patients who experience inconsistent high and low glucose levels, who experience hypoglycemia unawareness and who generally desire better control, as well as for women with gestational diabetes and pregnant women with diabetes.
